Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-280778 in Essential Hypertension
NCT01264692Phase 2Completed
- Sponsor
- Idorsia
- Start
- Feb 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ACT-280778 in essential hypertension (3 arms), sponsored by Idorsia. Primary endpoint: Sitting Diastolic Blood Pressure at 28 days. Started Feb 2011; status: completed.
02
Drugs
ACT-280778
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01264692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01264692.